688180 Shanghai Junshi Biosciences Co., Ltd.
- 25.14
- 0.000.00%
Shanghai Junshi Biosciences Co., Ltd. News
Junshi Bio: From a laboratory of less than 300 square meters in 2012 to a leading innovative drug | Zhangjiang's new productive forces
Currently, junshi bio has four innovative drugs, including Teripriline and Adamonab, which have achieved commercial sales. Zhang Zhuobing believes that the research and development of innovative drugs is endless, just like innovation itself. in order for the innovative drug industry to achieve long-term development, it needs to establish an effective system for the transformation of scientific research achievements, which directly affects the industrialization efficiency of biotech enterprises.
junshi bio (688180.SH): has repurchased 0.8159 million shares, and the repurchase plan has been completed.
On September 9th, Junshi Bio (688180.SH) announced that as of the disclosure date of this announcement, the company's share repurchase plan has been completed. The company repurchased a total of 0.8159 million shares through the Shanghai Stock Exchange trading system using centralized bidding trade, accounting for 0.0828% of the total share capital. The highest repurchase price was RMB 41.69 per share, and the lowest price was RMB 29.03 per share. The average repurchase price was RMB 37.85 per share, with a total fund payment of RMB 30,883,207.73 (excluding stamp duty, transaction commission and other fees).
Junshi Biosciences (688180.SH): Has repurchased 0.0828% of the shares.
On September 2, junshi bio (688180.SH) announced that as of August 31, 2024, the company has repurchased a total of 815,871 shares through the trading system of the Shanghai Stock Exchange by centralized bidding trading, accounting for 0.0828% of the total share capital of the company. The highest repurchase price was RMB 41.69 per share, and the lowest price was RMB 29.03 per share. The total amount paid was RMB 30,883,207.73 (excluding stamp duty, transaction commissions, and other trading fees).
Shanghai Junshi Biosciences' Losses Shrink 35% in H1 as Revenue Jumps 17%
Express News | Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
Junshi Biotech 2024 Semi-Annual Report
Junshi Biotech 2024 Semi-Annual Report Summary
junshi bio (688180.SH) released its semi-annual performance, with a net loss of 0.645 billion yuan, a narrowed year-on-year.
Junshi Bio (688180.SH) disclosed its 2024 semi-annual report, during the reporting period, the company achieved revenue of 7.86...
Junshi Bio (01877) plans to sell approximately 9.45% equity of Shanghai Anglyn Technology. It has subscribed approximately 9.45% of the issued share capital of Anglyn Technology, Cayman Islands.
Junshi Bio (01877) announced that as part of the restructuring of Shanghai Anlingke on August 30, 2024, ...
Express News | Shanghai Junshi Biosciences - Approved Co May Reduce Registered Capital It Held in Shanghai Junshi Xihai Biotechnology
junshi bio (01877) announced its interim performance, with a shareholder loss of 0.646 billion yuan, a year-on-year narrowing of approximately 35%.
junshi bio (01877) announced its interim results for the six months ended June 30, 2024, with a total group revenue of approximately...
JUNSHI BIO: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
Junshi Bio (688180.SH): Net loss of 640 million yuan in the first half of the year.
On August 30, Junshi Bio (688180.SH) released its semi-annual report. In the first half of 2024, the company achieved revenue of 0.786 billion yuan, a year-on-year growth of 17.37%, and a net income attributable to shareholders of the listed company of -0.64 billion yuan.
Express News | Junshi Biosciences Says H1 Net Loss at 645.0 Mln Yuan
Hong Kong stock concept tracking | Rich pipeline of IL-17A and other target drugs, institutions pay attention to the development of domestic IL-17A monoclonal antibodies (with concept stocks)
China Securities Co., Ltd. research believes that the Chinese self-immunity market is mainly focused on psoriasis and ankylosing spondylitis, with a potential to reach 24.7 billion US dollars by 2030.
Retail Investors Who Hold 40% of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Gained 6.4%, Insiders Profited as Well
Hong Kong stock abnormal | Junshi Bio (01877) rose more than 9% at the end of the day, and the 12th listing application for Toripalimab was accepted. A+H identity can retain Hong Kong Stock Connect qualification.
junshi bio (01877) rose more than 9% at the end of the day and at the time of publication, rose 9.17%, to HKD 12.38, with a turnover of HKD 19.5333 million.
Junshi Bio (01877) fell by 3.43% and was removed from the Hang Seng Composite SmallCap Index.
King's Financial News | The stock price of Junshi Bio (01877) continues to be under pressure, and the decline has expanded near midday, as of press time, the stock price is 11.26 Hong Kong dollars, down 3.43%, with a turnover of 73.931 million Hong Kong dollars. On the news side, on August 16, the Hang Seng Index Company announced the latest quarterly review results, in which Junshi Bio was removed from the Hang Seng Composite Small Cap Index. The changes will be implemented after the close of trading on Friday, September 6, 2024, and will take effect from Monday, September 9, 2024.
Junshi Bio (01877) has been removed from the Hang Seng Composite SmallCap Index.
On August 16th, Hang Seng Indexes Company published the latest quarterly review results, in which Junshi Bio (01877) was removed from the Hang Seng Composite SmallCap Index. The change will be implemented after the market closes on September 6th, 2024 (Friday) and will take effect from September 9th, 2024 (Monday).
Junshi Bio (01877.HK) held a board of directors meeting on August 30 to consider and approve its mid-year performance
Junshi Bio (01877.HK) announced on August 15th that the board of directors will hold a meeting on August 30th, 2024 (Friday) to consider and approve the group's mid-term performance for the six months ending on June 30th, 2024, as well as to handle other matters.
Analysis
Price Target
No Data
No Data